Organon & (US:OGN)2025-05-01 12:47Financial Performance - Revenue for Q1 2025 was $1.513 billion, a decrease of 7% as reported and 4% ex-FX, compared to $1.622 billion in Q1 2024[13, 53] - Adjusted EBITDA was $484 million, representing a 32% Adjusted EBITDA margin[13] - Adjusted diluted EPS was $1.02[13] - Free Cash Flow was $71 million, improved from $6 million in Q1 2024[30] Segment Performance - Women's Health franchise grew by 12% ex-FX, with total revenue of $463 million[17, 20] - Nexplanon is on track to achieve over $1 billion in revenue in 2025[20] - Biosimilars revenue was $141 million, a decrease of 15% ex-FX[21] - Established Brands revenue was $887 million, a decrease of 8% ex-FX[25] Geographic Performance - The U S represents approximately 27% of total Organon revenue[15] - Approximately 75% of FY sales are generated ex-US[15] Guidance and Outlook - Full year 2025 revenue guidance is unchanged at $6 125 billion-$6 325 billion[42] - The company anticipates a foreign exchange translation headwind of approximately $200 million, but there is potential upside at current rates[42]